Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody

Cheng Li; Wuqiang Zhan; Zhenlin Yang; Chao Tu; Yuanfei Zhu; Wenping Song; Keke Huang; Xiaodan Gu; Yu Kong; Xiang Zhang; Meng Zhang; Yi Zhang; Youhua Xie; Qiang Deng; Zhenguo Chen; Lu Lu; Shibo Jiang; Lei Sun; Yanling Wu; Tianlei Ying.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-474535

Documentos relacionados

  1. Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody.
  2. The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2.
  3. Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes.
  4. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
  5. Protective neutralizing epitopes in SARS-CoV-2.
  6. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.
  7. Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.
  8. Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection.
  9. SARS-CoV-2 Omicron BA.1 breakthrough infection drives late remodeling of the memory B cell repertoire in vaccinated individuals.
  10. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.